Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19391346 | 0.94 | HDAC2 (0.53) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL20482354 | 0.89 | SMN1; SMN2 (0.76) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL2422473 | 0.85 | HDAC8 (0.57) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL8247872 | 0.83 | ROCK2 (0.58) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL8255268 | 0.83 | ROCK2 (0.58) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL12052085 | 0.83 | ROCK2 (0.58) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL38658322 | 0.83 | SCN5A (0.56) | HDAC6HDAC8SMN1; SMN2HPGDRAB9A | |
| SCHEMBL250247 | 0.83 | HDAC6 (0.80) | HDAC6HDAC8HDAC2SMN1; SMN2HPGD | |
| SCHEMBL5943921 | 0.83 | HDAC6 (0.71) | HDAC6HDAC8HDAC2SMN1; SMN2RAB9A | |
| SCHEMBL12069255 | 0.82 | SCN5A (0.59) | HDAC6HDAC8SMN1; SMN2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023205794-A1 | COMBINATION THERAPY USING A PYRIMIDONE DERIVATIVE AS PTPN11 INHIBITOR AND A PD-1/PD-L1 INHIBITOR AND ITS USE IN THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| WO-2023168246-A2 | SELECTIVE G PROTEIN-COUPLED RECEPTOR KINASE 5 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-09-07 | — | — | WO | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| CN-100351228-C | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORP (KR) | 2007-11-28 | — | — | CN | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| CN-1839115-A | Hydroxamic acid derivatives and preparation method thereof | AMOREPACIFIC CORP (KR) | 2006-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | HDAC6 2467/4885HDAC8 3449/4885HDAC2 2683/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | HDAC6 2017/4885HDAC8 2116/4885HDAC2 2534/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HDAC6 1011/4885HDAC8 900/4885HDAC2 514/4885 |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | HDAC6 3011/4885HDAC8 2211/4885HDAC2 2261/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HDAC6 121/4885HDAC8 413/4885HDAC2 138/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | HDAC6 265/4885HDAC8 791/4885HDAC2 182/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | HDAC6 12/4885HDAC8 97/4885HDAC2 196/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | HDAC6 2041/4885HDAC8 1517/4885HDAC2 1915/4885 |
| US-20230302142-A1 | Cytotoxic Agents | ANXA11, ANXA5, HAX1 | HDAC6 4819/4885HDAC8 4098/4885HDAC2 4857/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | HDAC6 260/4885HDAC8 210/4885HDAC2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.